Percorten-V

Verify with FDA CVM →

12 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
1
Deaths Reported
830.0%
Death Rate

Active Ingredients

Percorten-V

Administration Routes

UnknownSubcutaneousIntramuscular

Species Affected

Dog 12

Most Affected Breeds

Retriever - Labrador 2
Mastiff 1
Hound - Basset 1
Boxer (German Boxer) 1
Shiba Inu 1
Deutsche Dogge, Great Dane 1
Shepherd Dog - German 1
Crossbred Canine/dog 1
Beagle 1
Poodle - Toy 1

Most Reported Reactions

Immediate pain upon injection 4
General pain (see other SOCs for specific pain) 2
Malaise 2
Weight loss 2
Elevated alanine aminotransferase (ALT) 2
Unable to jump 1
Neutrophilia 1
Lymphopenia 1
Sudden death 1
Vocalisation 1
Biting -aggression (see also 'Skin and appendages disorders') 1
Itching 1

Outcome Breakdown

Recovered/Normal
8 (66.7%)
Ongoing
2 (16.7%)
Outcome Unknown
1 (8.3%)
Died
1 (8.3%)

Data Summary

Metric Value
Total adverse event reports 12
Reports involving death 1
Case-fatality rate (reported events) 830.0%
Distinct species in reports 1
Distinct breeds in reports 11
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Percorten-V Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 12 adverse event reports referencing Percorten-V, including 1 reports in which the animal died — a 830.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Percorten-V. Reported administration routes include Unknown, Subcutaneous, Intramuscular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Percorten-V reports are Dog (12 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (2), Mastiff (1), Hound - Basset (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Percorten-V are Immediate pain upon injection (4), General pain (see other SOCs for specific pain) (2), Malaise (2), Weight loss (2). Of the 12 reports with a coded outcome, Recovered/Normal is the leading category at 66.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Percorten-V.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial